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Gemcitabine plus vinorel-
bine as an effective sal-
vage chemotherapeutic 
regimen in advanced 
Hodgkin lymphoma
To the Editor: About 20% to 
30% of Hodgkin lymphoma (HL) 
patients experience refractory or 
relapsed disease, for which effective 
salvage treatment is needed. Varied 
combination regimens with gem-
citabine and other agents such as 
cisplatin, vinorelbine, doxorubicin, 
ifosfamide and steroids have been 
evaluated for relapsed or refractory 
HL.1-3 These regimens generally 
have a favorable toxicity profile and 
overall response rate exceeds 70%. 
Vinorelbine is active as a single 
agent in heavily pretreated patients 
with HL and toxicity is mild and 
reversible. Thus, the inclusion of 
vinorelbine in second-line com-
bination chemotherapy regimens 
for HL is strongly recommended.4 
Gemcitabine plus vinorelbine (GV) 
proved to be effective in lung can-
cer, breast cancer and non-Hodgkin 
lymphoma.5-8 We report our expe-
rience using a GV regimen in two 
patients with advanced HL.
A 26-year-old woman pre-
sented with a huge right gluteal 
mass that had been present for 2 
months. HL, stage IIb, was diag-
nosed with an initial presentation 
of left submandibular, chest wall, 
and axillary lymph adenopathy. 
After 6 cycles of ABVD chemo-
therapy (doxorubicin, bleomycin, 
vinblastine, dacarbazine), complete 
remission (CR) was achieved. One 
year later, her disease relapsed. 
After 4 courses of ABVD, CR 
was achieved again. She visited her 
prior physician because of a pain-
less and huge mass over the right 
gluteal region for 2 months and 
disease relapse was diagnosed. She 
was transferred to our hospital. On 
physical examination, a fixed pal-
pable tough mass approximately 
15×15 cm was in the right gluteal 
region. MRI of the pelvis revealed 
a 16×14×16 cm lobulated and in-
filtrative lesion in the right gluteal 
region. Salvage chemotherapy with 
cisplatin and Ara-C was initiated. 
However, disease progression was 
noted after 6 courses of treatment. 
Rescue chemotherapy with etop-
side, solumedrol and cytaraine was 
administrated with poor response. 
MRI of the abdomen revealed hep-
atosplenomegaly with multiple ho-
mogeneous masses over both lobes 
of the liver and the spleen. HL 
with the liver and spleen involve-
ment was highly suspected. Rescue 
chemotherapy, with gemcitabine 
(1000 mg/m2) plus vinorelbine 
(25 mg/m2) days 1 and 8, every 21 
days, was started. After 3 courses 
of treatment, CR was achieved and 
allogenic peripheral blood stem-
cell transplantations were per-
formed in succession. Thirty-three 
months later, multiple progressive 
masses over the liver and spleen 
were found again and her disease 
progressed continuously with 
multiple lung involvement. After 
3 courses of GV, partial remission 
was achieved. She has continued 
the GV regimen treatment for up 
to 16 courses. She remains in stable 
disease and good general condition 
at the time of writing.
 The second case, a 48-year-old 
woman with type 2 diabetes melli-
tus and hypertensive cardiovascular 
disease on regular medication for 2-
3 years was transferred to our clinic 
for evaluation and treatment of HL. 
HL, stage II was diagnosed with ini-
tial presentation of a left neck mass. 
After 4 courses of ABVD, CR was 
achieved. Two years later, her disease 
progressed with recurrence of the 
left neck and mediastinal and para-
aortic lymphadenopathies. Salvage 
chemotherapy with ASHAP regi-
men was initiated. However, dis-
ease progression was noted after 1 
course of treatment. Then rescue 
chemotherapy, with gemcitabine 
(1000 mg/m2) plus vinorelbine (25 
mg/m2) on days 1 and 8, every 21 
days, was started. After 4 courses 
of treatment, CR was achieved. She 
has been followed up regularly at 
our outpatient department without 
recurrence as of the time of writing 
(about 3 years).
The results of this phase II study 
clearly confirm that vinorelbine is ef-
fective in patients with far-advanced 
HL previously treated with almost 
all conventional drugs and resistant 
to other cytotoxic alkaloids. Eghbali 
et al found that vinorelbine achieves 
a response rate as high as 90% after 
four cycles of therapy in advanced 
previously untreated Hodgkin dis-
ease.9,10 Thus, vinorelbine may rank 
as one of the most active agents in 
the management of HL.4 Arai et al 
performed a phase I study of GV as 
a part of conditioning regimen for 
autologous stem cell transplantation 
in combination with carmustine, 
etoposide and cyclophosphamide.11 
It was deemed that the conditioning 
regimen containing GV was worth 
further investigation.
The Cancer and Leukemia 
Group B has studied another com-
bination regimen (gemcitabine, 
vinorelbine and liposomal doxoru-
bicin) for refractory or relapsed HL, 
which CR and PR rates in the entire 
group were 19% and 51%, respec-
tively. The GV regimen reduces the 
side effects of liposomal doxorubi-
cin, which induces as heart arrhyth-
mias, neutropenia and alopecia and 
was still continuing good response. 
The GV regimen is reported to be 
effective in patients with advanced 
non-small cell lung cancer and 
metastatic breast cancer.10-11 The 
most common adverse effect ob-
served in GV-treated patients was 
hematological toxicity. In the study 
conducted by Chen et al,10 World 
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grade 3 or 4 myelosuppression was 
commonly noted (47.5% leucopenia, 
17.5% anemia, 12.5% thrombocy-
topenia). Both our patients experi-
enced grade 3 neutropenia, but there 
was no febrile neutropenia episode. 
Subsequent chemotherapy cycles 
could be conducted as scheduled 
with prophylactic filgrastim use. No 
obvious non-hematologic toxicities, 
such as nausea or vomiting, skin 
rash, and flu-like syndrome, were ob-
served. We suggest that the GV regi-
men be considered in the choice of 
rescue treatment for advanced HL. 
It is less toxic and well tolerated.
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